We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

bioMérieux

Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App




Novel Flu Test Developed to Speed Up Treatment

By LabMedica International staff writers
Posted on 20 Apr 2017
Print article
Image: The FilmArray multiplex polymerase chain reaction system used for point-of -care diagnosis of acute respiratory diseases (Photo courtesy of bioMérieux).
Image: The FilmArray multiplex polymerase chain reaction system used for point-of -care diagnosis of acute respiratory diseases (Photo courtesy of bioMérieux).
A novel way of using a swab test has been developed which can rapidly diagnose influenza and other viral infections in patients with severe respiratory conditions, resulting in shorter courses of antibiotics and less time in hospital.

Rapid point-of-care testing (POCT) for respiratory viruses might improve clinical care by reducing unnecessary antibiotic use, shortening length of hospital stay, improving influenza detection and treatment, and rationalizing isolation facility use; however, insufficient evidence exists to support its use over standard clinical care.

Doctors and their colleagues at University Hospital Southampton enrolled adults, aged equal to or over 18 years within 24 hours of presenting to the emergency department or acute medical unit of a large UK hospital with acute respiratory illness or fever higher than 37.5 °C for less than seven days duration, or both, over two winter seasons. Patients were randomly assigned (1:1), via an internet-based allocation sequence with random permuted blocks, to have a molecular POCT for respiratory viruses or routine clinical care.

Of the 301 (84%) of 360 patients in the POCT group received antibiotics compared with 294 (83%) of 354 controls and mean duration of antibiotics did not differ between groups (7·2 ± 5.1 days). The investigators found that 50/301(17%) of patients treated with antibiotics in the POCT group received single doses or brief courses of antibiotics (less than 48 hours) compared with 26 (9%) of 294 patients in the control group. Mean length of stay was shorter in the POCT group (5.7 ± 6·3 days) than in the control group (6·8 ± 7.7 days).

The authors concluded that patients who had the point-of-care test got the right treatment for their lung condition faster. In addition, patients who tested positive for influenza in the point-of-care testing group were appropriately isolated in a side room and given antiviral medication more often and sooner than those in the standard care group.

Tristan W Clark, MD, an associate professor in infectious diseases and senior author of the study, said, “My vision is that anyone who comes into hospital with an acute respiratory condition will receive this point-of-care test as soon as they come through the hospital door. It tells us immediately what virus the person has so, for example, if they have influenza they can be isolated in a side room and given antiviral drugs without delay.” The study was published on April 6, 2017, in the journal Lancet Respiratory Medicine.

Gold Member
Troponin T QC
Troponin T Quality Control
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Treponema Pallidum Test
ZEUS IFA Fluorescent Treponemal Antibody-Absorption (FTA-ABS) Test System
New
FAP Immunoassay
Quantikine QuicKit Human FAP ELISA

Print article

Channels

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.